Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

The Angels Initiative

Stroke prevention

  Liver Diseases

  Free Subscription


1 Am J Gastroenterol
2 BMC Cancer
3 BMC Gastroenterol
1 Br J Surg
4 Dig Dis
5 Dig Dis Sci
1 Endoscopy
1 Eur Radiol
2 Gastroenterology
14 Hepatology
1 Indian J Gastroenterol
5 J Hepatol
2 J Pediatr
2 Oncogene
1 PLoS Comput Biol
7 PLoS One
1 Transplantation

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Am J Gastroenterol

  1. MATCHETT CL, Rattan P, McConnell JP, Donato LJ, et al
    Chylous Ascites: Reassessment of Diagnostic Criteria in Patients With Portal Hypertension.
    Am J Gastroenterol. 2022 Nov 16. pii: 00000434-990000000-00561.
    PubMed         Abstract available

    BMC Cancer

  2. WANG P, Yang S, Li C, Han X, et al
    Nomogram-based development and evaluation for predictions of 30-day and 1-year survival in patients with spontaneously ruptured hepatocellular carcinoma.
    BMC Cancer. 2022;22:1177.
    PubMed         Abstract available

  3. LI XH, Zhao CY, Zhou EL, Lin XJ, et al
    Efficacy and safety of adjuvant chemotherapy in T1N0M0 intrahepatic cholangiocarcinoma after radical resection.
    BMC Cancer. 2022;22:1159.
    PubMed         Abstract available

    BMC Gastroenterol

  4. CHEN NY, Chen KH, Wang YW, Tsai HH, et al
    The impact of symptom distress on health-related quality of life in liver cancer patients receiving arterial chemoembolization: the mediating role of hope.
    BMC Gastroenterol. 2022;22:456.
    PubMed         Abstract available

  5. GOSWAMI P, Adeniran OR, K Frantz S, Matsuoka L, et al
    Overall survival and toxicity of Y90 radioembolization for hepatocellular carcinoma patients in Barcelona Clinic Liver Cancer stage C (BCLC-C).
    BMC Gastroenterol. 2022;22:467.
    PubMed         Abstract available

  6. HUANG X, Yan M, Deng Z, Yao L, et al
    Natural history of decompensated cirrhosis with serum hepatitis B DNA < 2000 IU/mL: a retrospective study.
    BMC Gastroenterol. 2022;22:452.
    PubMed         Abstract available

    Br J Surg

  7. WANG XH, Zhou QF, Wang CM, Xiang CL, et al
    Adjuvant transarterial chemoembolization for intermediate-stage hepatocellular carcinoma with microvascular invasion.
    Br J Surg. 2022 Nov 17. pii: 6832194. doi: 10.1093.

    Dig Dis

  8. MASIOR L, Grat M
    Primary Nonfunction and Early Allograft Dysfunction after Liver Transplantation.
    Dig Dis. 2022;40:766-776.
    PubMed         Abstract available

  9. GARRIDO I, Magalhaes A, Lopes J, Macedo G, et al
    Trastuzumab Emtansine-Induced Nodular Regenerative Hyperplasia: Is Dose Reduction Enough as a Preventable Measure?
    Dig Dis. 2022;40:787-792.
    PubMed         Abstract available

  10. KAM LY, Huang DQ, Teng MLP, Takahashi H, et al
    Clinical Profiles of Asians with NAFLD: A Systematic Review and Meta-Analysis.
    Dig Dis. 2022;40:734-744.
    PubMed         Abstract available

  11. ZHANG Y, Cai H, Wu MH, Zhu DH, et al
    miR-3682-3p activated by c-Myc aggravates the migration and stemness in hepatocellular carcinoma cells by regulating PTEN/PI3K/AKT/beta-catenin signaling.
    Dig Dis. 2022 Nov 10. pii: 000527800. doi: 10.1159/000527800.
    PubMed         Abstract available

    Dig Dis Sci

  12. CURRAN C, Priest M, Datta S, Forrest EH, et al
    Hepatocellular Carcinoma Risk Scores Predict Patients Under Surveillance at Low Risk of Benefit and High Risk of Harm.
    Dig Dis Sci. 2022 Nov 14. pii: 10.1007/s10620-022-07731.
    PubMed         Abstract available

  13. HORVATITS T, Mahmud N, Serper M, Seiz O, et al
    MELD-Lactate Predicts Poor Outcome in Variceal Bleeding in Cirrhosis.
    Dig Dis Sci. 2022 Nov 14. pii: 10.1007/s10620-022-07744.
    PubMed         Abstract available

  14. CHENG S, Yu E, Garacci Z, Erwin AL, et al
    Prevalence of Undiagnosed Acute Hepatic Porphyria in Cyclic Vomiting Syndrome and Overlap in Clinical Symptoms.
    Dig Dis Sci. 2022 Nov 16. pii: 10.1007/s10620-022-07756.
    PubMed         Abstract available

  15. SINHA A, Bhuva M, Grant C, Gimson AE, et al
    ABCB4 Mutations in Adults Cause a Spectrum Cholestatic Disorder Histologically Distinct from Other Biliary Disease.
    Dig Dis Sci. 2022 Mar 14. pii: 10.1007/s10620-022-07416.
    PubMed         Abstract available

  16. HENSON JB, Helzberg JH, Muir AJ
    Patient-Predicted Outcomes Are Associated with Quality of Life in Patients with Primary Sclerosing Cholangitis.
    Dig Dis Sci. 2022 Mar 28. pii: 10.1007/s10620-022-07482.
    PubMed         Abstract available


  17. MURAKAMI M, Fujimori N, Kaku T
    Peroral direct cholangioscopy using balloon endoscopy for massive bile duct stones after Roux-en-Y hepaticojejunostomy.
    Endoscopy. 2022 Nov 11. doi: 10.1055/a-1959-1500.

    Eur Radiol

  18. CAI Q, Mao Y, Dai S, Gao F, et al
    The growth pattern of liver metastases on MRI predicts early recurrence in patients with colorectal cancer: a multicenter study.
    Eur Radiol. 2022;32:7872-7882.
    PubMed         Abstract available


  19. ZHANG H, Peng Y, Tang X
    Comments on "Diversity, Equity, and Inclusion in Gastroenterology and Hepatology: A Survey of Where We Stand".
    Gastroenterology. 2022 Nov 14. pii: S0016-5085(22)01271.

  20. WANG Z, Tai Y, Wu H
    A rare cause of abdominal pain after transjugular intrahepatic portosystemic shunt.
    Gastroenterology. 2022 Nov 10. pii: S0016-5085(22)01258.


  21. ASIF B, Ortiz V, Conboy CB, Diaz LA, et al
    Hepatology Highlights.
    Hepatology. 2022;76:1555-1556.

  22. HONG F, Lin CY, Yan J, Dong Y, et al
    Canopy Homolog 2 contributes to liver oncogenesis by promoting unfolded protein response-dependent destabilization of tumor protein P53.
    Hepatology. 2022;76:1587-1601.
    PubMed         Abstract available

  23. FENG R, Kan K, Sticht C, Li Y, et al
    A hierarchical regulatory network ensures stable albumin transcription under various pathophysiological conditions.
    Hepatology. 2022;76:1673-1689.
    PubMed         Abstract available

  24. HUANG M, Jiao J, Cai H, Zhang Y, et al
    C-C motif chemokine ligand 5 confines liver regeneration by down-regulating reparative macrophage-derived hepatocyte growth factor in a forkhead box O 3a-dependent manner.
    Hepatology. 2022;76:1706-1722.
    PubMed         Abstract available

  25. RATZIU V, Anstee QM, Wong VW, Schattenberg JM, et al
    An international survey on patterns of practice in NAFLD and expectations for therapies-The POP-NEXT project.
    Hepatology. 2022;76:1766-1777.
    PubMed         Abstract available

  26. SHARMA D, Ben Yakov G, Kapuria D, Viana Rodriguez G, et al
    Tip of the iceberg: A comprehensive review of liver disease in Inborn errors of immunity.
    Hepatology. 2022;76:1845-1861.
    PubMed         Abstract available

  27. KIM Y, Chang Y, Ryu S, Wild SH, et al
    NAFLD improves risk prediction of type 2 diabetes: with effect modification by sex and menopausal status.
    Hepatology. 2022;76:1755-1765.
    PubMed         Abstract available

  28. SMIRNOVA E, Muthiah MD, Narayan N, Siddiqui MS, et al
    Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
    Hepatology. 2022 May 13. doi: 10.1002/hep.32568.
    PubMed         Abstract available

  29. SINN DH, Kang D, Kang M, Guallar E, et al
    Nonalcoholic fatty liver disease and accelerated loss of skeletal muscle mass: A longitudinal cohort study.
    Hepatology. 2022;76:1746-1754.
    PubMed         Abstract available

  30. HARTL L, Haslinger K, Angerer M, Semmler G, et al
    Progressive cholestasis and associated sclerosing cholangitis are frequent complications of COVID-19 in chronic liver disease patients.
    Hepatology. 2022 May 21. doi: 10.1002/hep.32582.
    PubMed         Abstract available

  31. SHEARER AM, Wang Y, Fletcher EK, Rana R, et al
    PAR2 promotes impaired glucose uptake and insulin resistance in NAFLD through GLUT2 and Akt interference.
    Hepatology. 2022;76:1778-1793.
    PubMed         Abstract available

  32. XUN Z, Zhao H
    Letter to the editor: Is NAFLD a bystander or contributor to coronary artery disease?
    Hepatology. 2022;76:E127-E128.

  33. JIANG ST, Zhang L, Xu YY, Lu X, et al
    Letter to the editor: Complications following SARS-CoV-2 infection in patients with chronic liver disease.
    Hepatology. 2022;76:E116.

  34. ZHANG J, Xu Y, Lu X, Zhao H, et al
    Letter to the editor: NAFLD and sarcopenia: Association or causation?
    Hepatology. 2022;76:E119-E120.

    Indian J Gastroenterol

  35. GHADIRI F, Husseini AA, Oztas O
    A machine-learning approach for nonalcoholic steatohepatitis susceptibility estimation.
    Indian J Gastroenterol. 2022 Nov 11. pii: 10.1007/s12664-022-01263.
    PubMed         Abstract available

    J Hepatol

  36. BAJAJ JS
    Albumin for Liver-Brain Outcome Improvement Across Different Situations in Cirrhosis.
    J Hepatol. 2022 Nov 15. pii: S0168-8278(22)03298.

  37. SANYAL AJ, Foucquier J, Younossi ZM, Harrison SA, et al
    Enhanced diagnosis of advanced fibrosis and cirrhosis in individuals with NAFLD using FibroScan-based Agile scores.
    J Hepatol. 2022 Nov 11. pii: S0168-8278(22)03293.
    PubMed         Abstract available

  38. SHEN W, Middleton MS, Cunha GM, Delgado TI, et al
    Changes in abdominal adipose tissue depots accessed by MRI correlate with hepatic histologic improvement in non-alcoholic steatohepatitis.
    J Hepatol. 2022 Nov 8. pii: S0168-8278(22)03284.
    PubMed         Abstract available

  39. CHEN S, Lu Z, Jia H, Yang B, et al
    Hepatocyte-specific Mas activation enhances lipophagy and fatty acid oxidation to protect against acetaminophen-induced hepatotoxicity in mice.
    J Hepatol. 2022 Nov 9. pii: S0168-8278(22)03285.
    PubMed         Abstract available

  40. ZHANG X, Song J, Zhang Y, Wen B, et al
    Baveno VII algorithm outperformed other models in ruling out high-risk varices in individuals with HBV-related cirrhosis.
    J Hepatol. 2022 Nov 7. pii: S0168-8278(22)03287.
    PubMed         Abstract available

    J Pediatr

  41. KHURANA T, Klepper C, Fei L, Sun Q, et al
    Clinically Meaningful Body Mass Index Change Impacts Pediatric Nonalcoholic Fatty Liver Disease.
    J Pediatr. 2022;250:61-66.
    PubMed         Abstract available

  42. HADZIC N, Molnar E, Height S, Kovacs G, et al
    J Pediatr. 2022 Jul 11. pii: S0022-3476(22)00625.
    PubMed         Abstract available


  43. JIN C, Han-Hua D, Qiu-Meng L, Deng N, et al
    MTDH-stabilized DDX17 promotes tumor initiation and progression through interacting with YB1 to induce EGFR transcription in Hepatocellular Carcinoma.
    Oncogene. 2022 Nov 17. pii: 10.1038/s41388-022-02545.
    PubMed         Abstract available

  44. ZHANG H, Liao Z, Wang W, Liu Y, et al
    A micropeptide JunBP regulated by TGF-beta promotes hepatocellular carcinoma metastasis.
    Oncogene. 2022 Nov 15. pii: 10.1038/s41388-022-02518.
    PubMed         Abstract available

    PLoS Comput Biol

  45. LEE CY, Chen Y, Duan Z, Xu M, et al
    Venus: An efficient virus infection detection and fusion site discovery method using single-cell and bulk RNA-seq data.
    PLoS Comput Biol. 2022;18:e1010636.
    PubMed         Abstract available

    PLoS One

  46. COLAK N, Bayrak Basakci O, Bayram B, Aksay E, et al
    Optic nerve sheath diameter in patients with hepatic encephalopathy.
    PLoS One. 2022;17:e0277643.
    PubMed         Abstract available

  47. SHEARN CT, Anderson AL, Devereux MW, Orlicky DJ, et al
    The autophagic protein p62 is a target of reactive aldehydes in human and murine cholestatic liver disease.
    PLoS One. 2022;17:e0276879.
    PubMed         Abstract available

  48. GROBBEE EJ, de Jong VD, Schrieks IC, Tushuizen ME, et al
    Improvement of non-invasive tests of liver steatosis and fibrosis as indicators for non-alcoholic fatty liver disease in type 2 diabetes mellitus patients with elevated cardiovascular risk profile using the PPAR-alpha/gamma agonist aleglitazar.
    PLoS One. 2022;17:e0277706.
    PubMed         Abstract available

  49. MENA E, Shih J, Chung JY, Jones J, et al
    Functional Imaging of Liver Cancer (FLIC): Study protocol of a phase 2 trial of 18F-DCFPyL PET/CT imaging for patients with hepatocellular carcinoma.
    PLoS One. 2022;17:e0277407.
    PubMed         Abstract available

  50. KIYOAKI I, Sumida Y, Nakade Y, Okumura A, et al
    Mac-2 binding protein glycosylation isomer, the FIB-4 index, and a combination of the two as predictors of non-alcoholic steatohepatitis.
    PLoS One. 2022;17:e0277380.
    PubMed         Abstract available

  51. LAOCHAREONSUK W, Surachat K, Chiengkriwate P, Sangkhathat S, et al
    A novel pathogenesis concept of biliary atresia approached by combined molecular strategies.
    PLoS One. 2022;17:e0277334.
    PubMed         Abstract available

  52. WANG S, Wang G, Lu S, Zhang J, et al
    Proteome expression profiling of red blood cells during the tumorigenesis of hepatocellular carcinoma.
    PLoS One. 2022;17:e0276904.
    PubMed         Abstract available


  53. HSU YC, Chen CH, Huang HF, Lee YT, et al
    Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus.
    Transplantation. 2022 Nov 16. pii: 00007890-990000000-00249.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.